Global Clinical Research Industry’s Commitment to COVID-19 Collaboration

The Association of Clinical Research Organizations (ACRO) and its
members are committed to collaborating with biopharmaceutical
organizations worldwide to develop vaccines and anti-viral therapies to prevent, diagnose, and treat COVID-19.

Slide Image
The Voice of the Global Clinical Research Industry

The Association of Clinical Research Organizations (ACRO) represents companies at the forefront of global clinical research. ACRO members are committed to innovation in clinical development and thought leadership in research policy on topics like RBM and RBQM.

Slide Image
previous arrow
next arrow
Slider

COVID-19 Resource Center

Click here to find guidance from regulators.

ACRO's Response to COVID-19

Click here for ACRO’s latest statements on the COVID-19 pandemic.

ACRO Member Corner on COVID-19

Click here to see how member companies are responding to COVID-19.

US Regulatory Policy

Half of all clinical trials occur in the US. ACRO works with US legislators and regulators to ensure a positive regulatory environment that supports high-quality, safe and ethical clinical research. More »

European Advocacy

ACRO engages with European regulators, connecting its members with critical stakeholders. We support the clinical research industry and provide CRO expertise. More »

CRO Forum

ACRO’s CRO Forum is a formal mechanism to enable clinical research organizations to interact with TransCelerate BioPharma Inc. on a range of issues that impact the industry. More »

Clinical Research Roundtables

In Europe and the US, ACRO gathers government leaders and key stakeholders to inform, educate and promote the unique contributions of clinical research and technology companies. More »

Addressing Industry Pain Points

We help create a predictable, enabling business environment. ACRO’s proactive agenda is focused on policy outcomes that advance specific operational interests of ACRO members. More »

Data Protection & Privacy

ACRO’s Global Data Protection & Privacy Committee advances issues of data privacy, protection and security, and how the industry interprets policies and prepares for upcoming legislation. More »

Subscribe

Get ACRO’s free quarterly newsletter to stay informed about our work and the industry.

Join ACRO and Add Your Voice

We help create a global regulatory and business environment
where ACRO members succeed

News and Comments

Read More
News

2020 Officers and New Member Announcement

December 17, 2019

Washington DC – The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Alistair…

Read More
News

ACRO hosts Congressional Briefing on clinical research advancements

October 24, 2019

On Wednesday, October 23, 2019, ACRO hosted a Congressional Briefing on Capitol Hill. With the help of the Congressional Research & Development…

Read More
NewsReports

A Consistent Approach to Risk Based Quality Management: Collaboration is Key

October 24, 2019

Developing, executing and overseeing clinical trials is a complex process. Yet it is essential to gain reliable evidence from clinical trials to…

Read More
NewsReports

New ACRO Report Quantifies Benefits of RBM for Quality Reviews

October 17, 2019

A new report based on a survey of ACRO members reveals that Risk-Based Monitoring (RBM) makes clinical trial quality review more efficient…

Read More
News

Advancing the Adoption of Risk-Based Monitoring Strategies in Clinical Trials

August 16, 2019

On July 17, 2019, under cooperative agreement with the FDA, the Duke-Margolis Center for Health Policy (Duke Margolis) held a public workshop. The event, titled Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations, aimed to identify opportunities to improve Risk Based Monitoring (RBM) implementation and solicit stakeholder input on the challenges, barriers, and enablers that impact the successful adoption of RBM.

Read More
NewsPress Releases

ACRO offers unique insights on risk-based monitoring of clinical trials, calls for adoption of RBM as a best practice

May 16, 2019

Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, ACRO this week submitted extensive comments on recent FDA Guidance.Increasing the use of innovative RBM technologies helps make clinical trials safer, more efficient and higher quality. ACRO’s comments offer unique insights into the recent expansion of RBM implementation and call for further increasing the use of these oversight technologies.

ACRO Members